A5031399437- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Synthesis and biological activity
- Molecular Biology Techniques and Applications
- Quinazolinone synthesis and applications
- RNA modifications and cancer
- Advanced biosensing and bioanalysis techniques
- Reproductive System and Pregnancy
- Kruppel-like factors research
- Genomics and Rare Diseases
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
- Acute Lymphoblastic Leukemia research
- Synthesis and Biological Evaluation
- Genetic Syndromes and Imprinting
- Enzyme Structure and Function
- Pregnancy and preeclampsia studies
- Epigenetics and DNA Methylation
- Brain Metastases and Treatment
- Nuclear Structure and Function
- Multiple Myeloma Research and Treatments
- Melanoma and MAPK Pathways
- Cancer Mechanisms and Therapy
- Hemoglobinopathies and Related Disorders
- Medical Imaging Techniques and Applications
NeoGenomics (United States)
2020-2025
Salk Institute for Biological Studies
2013-2021
University of California, San Diego
2018-2019
Universidad Nacional de Córdoba
1999-2007
Universidad de Oviedo
1994
Significance Tumor cells are heterogeneous, and much variation occurs at the single-cell level, which may contribute to therapeutic response. Here, we studied drug resistance dynamics in a model of tolerance with metastatic breast cancer cell line by leveraging power RNA-Seq technology. Drug-tolerant within single clone rapidly express high cell-to-cell transcript variability, gene expression profile similar untreated cells, population reacquires paclitaxel sensitivity. Our nucleotide...
Abstract Background: Co-occurrence of gene alterations often plays a relevant role in the selection potential targeted therapies for cancer patient. It has been reported that patients with fusions respond to fusion-targeted therapy regardless tissue type. Less is known about co-occurrence SNVs and Indels copy number variation. Methods: Data from 795 tested CGP assay interrogated SNVs/Indels on 517 genes, 59 CNV 55 genes were included study. Variant clinical significance was determined as...
The nuclear protein CCCTC-binding factor (CTCF) has diverse roles in chromatin architecture and gene regulation. Functionally, CTCF associates with thousands of genomic sites interacts proteins, such as cohesin, or non-coding RNAs to facilitate specific transcriptional programming. In this study, we examined during the cellular stress response human primary cells using immune-blotting, quantitative real time-PCR, immunoprecipitation-sequence (ChIP-seq) analysis, mass spectrometry, RNA...
The human core promoter binding protein (hCPBP) has been identified as a DNA-binding involved in the regulation of TATA box-less genes like those encoding pregnancy-specific glycoproteins. Structurally, hCPBP contains three zinc fingers C-terminal domain, which is highly conserved number proteins that constitute Krüppel-like family transcription factors. In present work, we report molecular cloning mouse CPBP (mCPBP) and its expression pattern during development well adult tissues. cDNA...
Abstract Introduction: In many instances in Precision Oncology Medicine fragmented DNA from formalin-fixed paraffin-embedded (FFPE) samples is the only option. The majority of such degradedsamples need to be sequenced using next generation sequencing (NGS) [1]. Standardizedguidelines highlight that a minimum 500 × coverage depth required for tissue analyses [2].However, isn’t metric successful NGS analysis. Highly uniformDNA libraries allow clinical labs generate more hits their screens,...
11185 Background: The landscape of actionable genes significantly influences clinical decisions in cancer diagnosis, prognosis, and treatment planning. In a context, the selection NGS panels hinges on striking balance among informative data, insurance coverage, preferences patients healthcare providers. Molecular pathology reference laboratories commonly employ large-scale next-generation sequencing (NGS) testing, curating smaller, disease-specific targeted panels. This study investigates...
e15186 Background: Gene fusions have important implications for therapeutic selection and patient quality of care many are targeted effectively in a tumor type agnostic manner. While most assays detect hundreds at once, typically the results masked analyzed according to medical requisition. Unfortunately, patients community setting often only tested NTRK fusions, which prevalence ~ 1%, following positive IHC screen result. Here we compared side by clinical actionability gap when using panTRK...
Abstract A graphical method for the analysis of orientation planar and linear structural elements in drill core is presented. Simple computation projection operations applied to data taken from traced on cylindrical surface are required. To know a element(s) reference, requires detailed geology around hole.
Abstract Background: Incorporating gene fusions into a comprehensive profile is critical not only because very effective therapies targeting oncogenic fusion proteins exist but they may also negate the response to therapy of an actionable SNV and InDel mutations. We examined co-occurrence detected by RNA-seq with SNVs/InDels immunotherapy biomarker, PD-L1. Methods: In 2021, 5341 FFPE samples were analyzed our clinical laboratory using novel hybridization-based RNA sequencing assay. DNA...
Abstract Cancer recurrence and metastatic tumors might arise not only from residual primary tumor cells but even precancerous that are able to spread seed distant organs. Thus, pre-neoplastic neoplastic persist following treatment constitute an ideal evolutionary niche for cancer evolution. We have investigated the role of TGF-beta; signaling pathway, which is widely known as a pro-metastatic in late stages progression, context cellular response genotoxic stress induced by chemotherapy...
Abstract The notion that most cancers are ecosystems of evolving clones is now widely accepted. Hence, residual neoplastic cells persist following treatment constitute an ideal evolutionary niche from which recurrent arise and a major obstacle to the successful human cancers. We have identified TGFβ signaling contribute drug resistance by coordinately repressing transcription translation p53 in precancerous cancer cells. However, molecular events accompanying evolution towards tolerant...
<div>Abstract<p>EGFR-activating mutations are observed in approximately 15% to 20% of patients with non–small cell lung cancer. Tyrosine kinase inhibitors have provided an illustrative example the successes targeting oncogene addiction cancer and role tumor-specific adaptations conferring therapeutic resistance. The compound osimertinib is a third-generation tyrosine inhibitor, which was granted full FDA approval March 2017 based on EGFR T790M has received additional as...
<p>EGFR Receptor Signaling and Bypass Pathways</p>